PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
18722223-1	2008	OBJECTIVE: To determine the efficacy of proton pump inhibitor (PPI) therapy with esomeprazole on symptoms and signs associated with laryngopharyngeal reflux (LPR).	Esomeprazole	81-93	ATPase H+/K+ transporting subunit alpha	Homo sapiens	40-51	
22033211-2	2011	Vimovo, a combination of the NSAID naproxen and the proton pump inhibitor (PPI) esomeprazole, is also approved by the FDA for prevention of NSAID-associated gastric ulcers.	Esomeprazole	80-92	ATPase H+/K+ transporting subunit alpha	Homo sapiens	52-63	
19125549-0	2009	Proton-pump inhibitor utilization associated with the change to nonpreferred formulary status for esomeprazole in the TRICARE formulary.	Esomeprazole	98-110	ATPase H+/K+ transporting subunit alpha	Homo sapiens	0-11	
17073837-8	2006	However, proton pump inhibitor (PPI) therapy was associated with significantly greater rates of both GU and DU healing than ranitidine; 8-week GU rates were 92% and 88% with esomeprazole 40 mg and 20 mg, respectively (vs. 74% with ranitidine, p < 0.01).	Esomeprazole	174-186	ATPase H+/K+ transporting subunit alpha	Homo sapiens	9-20	
34656072-0	2022	Effect of the Proton Pump Inhibitor Esomeprazole on the Systemic Exposure of Capecitabine: Results of A Randomized Crossover Trial.	Esomeprazole	36-48	ATPase H+/K+ transporting subunit alpha	Homo sapiens	14-25